Endlyz Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$17.3M
- Investors
-
7
Endlyz Therapeutics General Information
Description
Developer of disease-modifying therapeutics designed to restore endo-lysosomal function and abrogate neurodegeneration. The company specializes in developing technology that restores endo-lysosomal function and abrogates neurodegeneration in Parkinson's disease (PD) and other dementias, enabling patients to prevent the disease in the early stages.
Contact Information
Website
www.endlyz.comCorporate Office
- 1st Floor, 71 Kingsway
- London WC2B 6ST
- England, United Kingdom
Corporate Office
- 1st Floor, 71 Kingsway
- London WC2B 6ST
- England, United Kingdom
Endlyz Therapeutics Timeline
Endlyz Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Seed Round | 28-Apr-2026 | $17.3M | Completed | Startup | ||
| 4. Debt - General | 01-Feb-2023 | Completed | Startup | |||
| 3. Seed Round | 29-Jul-2021 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. University Spin-Out | 01-Jan-2021 | Completed | Startup |
Endlyz Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-3 | ||||||||
| Seed-2 | ||||||||
| Seed | 3,046,154 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 6.13% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Endlyz Therapeutics Signals
Endlyz Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| CD3 Leuven | Venture Capital | Minority | ||
| Oxford Science Enterprises | Venture Capital | Minority | ||
| Parkinson's UK | Corporation | Minority | ||
| SV Health Investors | PE/Buyout | Minority |
Endlyz Therapeutics FAQs
-
When was Endlyz Therapeutics founded?
Endlyz Therapeutics was founded in 2021.
-
Where is Endlyz Therapeutics headquartered?
Endlyz Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Endlyz Therapeutics?
Endlyz Therapeutics has 7 total employees.
-
What industry is Endlyz Therapeutics in?
Endlyz Therapeutics’s primary industry is Drug Discovery.
-
Is Endlyz Therapeutics a private or public company?
Endlyz Therapeutics is a Private company.
-
What is the current valuation of Endlyz Therapeutics?
The current valuation of Endlyz Therapeutics is .
-
What is Endlyz Therapeutics’s current revenue?
The current revenue for Endlyz Therapeutics is .
-
How much funding has Endlyz Therapeutics raised over time?
Endlyz Therapeutics has raised $23.4M.
-
Who are Endlyz Therapeutics’s investors?
AbbVie Ventures, CD3 Leuven, Oxford Science Enterprises, Parkinson's UK, and SV Health Investors are 5 of 7 investors who have invested in Endlyz Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process